How a Ketogenic Diet Affects Hormones and Metabolism in Women (SHEKAN)
Strategic Hormonal Evaluation in Keto-Adaptation
This study is looking at how a ketogenic diet (a way of eating that is high in fat and very low in carbohydrates) affects hormones, metabolism, and body composition in healthy women who have regular menstrual cycles. While ketogenic diets have become popular and have been studied in men and in people with certain health conditions, much less is known about how this way of eating affects the hormones and cycles of healthy, premenopausal women.
Researchers believe that a ketogenic diet may cause measurable changes in reproductive hormones (such as estrogen and progesterone), metabolic markers (like ketone and cholesterol levels), and body composition (such as body fat and lean muscle mass) across the menstrual cycle. The study will also explore whether the diet affects mood, sleep, and overall well-being.
Participants will follow a ketogenic diet for 12 weeks, roughly covering three menstrual cycles. During the first month, they will receive help with meal planning and food, and for the remaining weeks they will follow the diet on their own with continued support from a dietitian. Throughout the study, participants will check in weekly for blood draws, body composition scans, and a resting metabolism test, and will use at-home tools such as a smart ring and daily finger-stick tests to track their ketone levels and hormone patterns. Participants will also complete surveys about their mood, sleep, and general well-being.
By studying these changes closely, the research team hopes to better understand how a ketogenic diet affects women's health and hormones, which could help guide future dietary recommendations designed specifically for women.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
etogenic diets induce a metabolic shift from glucose to fat as the primary energy substrate, resulting in nutritional ketosis and associated changes in insulin sensitivity, lipid profiles, and body composition. While ketogenic diets have been studied extensively in the context of epilepsy, obesity, type 2 diabetes, and neurodegenerative disease, most existing research either underrepresents women or fails to account for hormonal fluctuations across the menstrual cycle. Preliminary evidence suggests that sex hormones and substrate metabolism differ meaningfully between men and women in their response to dietary interventions, yet these differences remain poorly characterized during ketogenic adaptation, particularly in healthy, regularly menstruating women.
This pilot study is designed to characterize the physiological, hormonal, metabolic, and behavioral adaptations that occur during a 12-week, well-formulated ketogenic diet in healthy, premenopausal women, capturing data across approximately three consecutive menstrual cycles. The diet is structured in two phases: an initial 4-week period with controlled feeding support (grocery provision or meal delivery services matched to individual caloric needs), followed by 8 weeks of self-guided dietary adherence supported by ongoing dietitian consultation and educational materials. Dietary adherence and ketosis status (target: ≥0.5 mmol/L blood BHB) are monitored daily via at-home fingerstick testing.
Participants attend weekly in-person study visits for the duration of the 12-week intervention, during which fasting venous blood is drawn to assess reproductive hormone levels, resting metabolic rate is measured via indirect calorimetry, and body composition is tracked using bioelectrical impedance (InBody). Full-body DXA scans, which provide a more precise measure of fat mass, lean mass, and visceral adiposity, are performed only at baseline and at the final Week 16 visit, in order to limit participants' cumulative radiation exposure. Menstrual cycle phase and ovulatory status are tracked continuously using a wearable basal body temperature ring and urine-based hormone test strips, allowing the research team to align hormonal blood draws with specific points in each participant's cycle. Validated PROMIS instruments are used to assess mood, sleep quality, anxiety, depression, and cognitive function at scheduled intervals throughout the study.
As a pilot study, SHEKAN is designed primarily to assess feasibility and estimate effect sizes to inform the design of future, larger-scale investigations, rather than to test a specific hypothesis with adequate statistical power to detect small between-group differences. Findings are intended to help characterize sex-specific responses to ketogenic diets and inform future research and clinical guidance regarding women's metabolic and reproductive health during dietary intervention.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43210
- Recrutement
- Physical Activity and Educational Services Building
-
Contact:
- Program Manager Department of Human Sciences - Kinesiology
- Numéro de téléphone: 6142470287
- E-mail: roe.236@osu.edu
-
Chercheur principal:
- Madison Kackley, PhD, Kinesiology
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy Women aged 18-40
- Self-reported, 27-32 day menstrual cycles
- Must have access to a smartphone, tablet or computer to access the diet survey and resources
- Must be willing to self-report menstrual cycles
Exclusion Criteria:
- History of reproductive disorders
- Pregnancy or lactation during the study period
- Recurring disordered eating behaviors or other food security concerns
- Suffered a lower body injury in the last 6 months
- Other major health concerns
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Ketogenic Diet Intervention Group
Healthy, premenopausal women (ages 18-40) with regular menstrual cycles will follow a 12-week well-formulated ketogenic diet designed to maintain nutritional ketosis (≥0.5 mmol/L BHB). During the first 4 weeks, participants receive controlled feeding support (grocery provision or meal delivery services). Weeks 5-12 transition to a self-guided ketogenic diet with continued dietitian support and educational resources. Participants undergo weekly in-person study visits (blood draws, resting metabolic rate testing, body composition scans, and validated surveys) plus daily at-home monitoring (fingerstick ketone/glucose testing, nightly wearable ring, and urine ovulation tracking) across approximately 16 weeks total, including baseline and final follow-up visits. |
A high-fat, low-carbohydrate, moderate-protein diet intended to induce and maintain nutritional ketosis over 12 weeks, with an initial 4-week period of controlled feeding support followed by 8 weeks of self-guided adherence with dietitian consultation and educational materials. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Ovulatory Status
Délai: Baseline to 12 weeks
|
To evaluate whether ketogenic dietary intervention or exogenous ketone supplementation restores ovulatory function in women with Polycystic Ovary Syndrome (PCOS). Ovulatory status will be assessed using a combination of validated measures, including basal body temperature monitoring via BBT, urinary luteinizing hormone (LH) surge detection using ovulation predictor kits, and serum progesterone levels. Participants will be classified as ovulatory or anovulatory based on hormonal and temperature cycle confirmation. |
Baseline to 12 weeks
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Serum Progesterone Concentration (ng/mL)
Délai: Baseline to 12 weeks
|
To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum progesterone will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation. |
Baseline to 12 weeks
|
|
Change in Serum Estradiol Concentration (pg/mL)
Délai: Baseline to 12 weeks
|
To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum estradiol will be analyzed using commercially available immunoassay kits (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation. |
Baseline to 12 weeks
|
|
Change in Serum Luteinizing Hormone Concentration (mIU/mL)
Délai: Baseline to 12 weeks
|
To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum luteinizing hormone (LH) will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation. |
Baseline to 12 weeks
|
|
Change in Serum Follicle Stimulating Hormone Concentrations (mIU/mL)
Délai: Baseline to 12 weeks
|
To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum follicle-stimulating hormone (FSH) will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation. |
Baseline to 12 weeks
|
|
Change in Daily Fasting BHB (mmol/L)
Délai: Baseline to 12 weeks (Daily)
|
To assess changes in metabolic parameters including fasting β-hydroxybutyrate (BHB). Capillary ketones will be measured daily using KetoMojo handheld monitors. |
Baseline to 12 weeks (Daily)
|
|
Change in Daily Fasting Glucose (mg/dL)
Délai: Baseline to 12 weeks (Daily)
|
To assess changes in metabolic parameters including fasting glucose. Capillary glucose will be measured daily using KetoMojo handheld monitors. |
Baseline to 12 weeks (Daily)
|
|
Change in Serum Insulin Concentration (µIU/mL)
Délai: Baseline to 12 weeks
|
To assess the effect of ketogenic diet and exogenous ketone supplementation on fasting insulin levels. Serum insulin will be measured at laboratory visits via immunoassay (Quest Diagnostics or validated ELISA). Mean change from baseline will be compared across groups. |
Baseline to 12 weeks
|
|
Change in Serum Total Cholesterol Concentration (mg/dL)
Délai: Baseline to 12 weeks
|
To assess changes in fasting serum total cholesterol in response to ketogenic diet and exogenous ketone supplementation. Blood samples will be collected biweekly and analyzed using standard clinical chemistry methods (Quest Diagnostics). Mean change from baseline to 12 weeks will be reported. |
Baseline to 12 weeks
|
|
Change in Serum Triglyceride Concentration (mg/dL)
Délai: Baseline to 12 weeks
|
To determine the effect of ketogenic diet and exogenous ketone supplementation on fasting triglyceride concentrations. Serum triglycerides will be measured via standard lipid panel. Mean change from baseline to 12 weeks will be compared across groups. |
Baseline to 12 weeks
|
|
Change in Serum LDL Cholesterol Concentration (mg/dL)
Délai: Baseline to 12 weeks
|
To assess the effect of ketogenic diet and exogenous ketone supplementation on fasting low-density lipoprotein (LDL) cholesterol. Serum LDL will be measured via standard lipid panel (Quest Diagnostics). Mean change from baseline to post-intervention will be reported. |
Baseline to 12 weeks
|
|
Change in Serum HDL Cholesterol Concentration (mg/dL)
Délai: Baseline to 12 weeks
|
To evaluate changes in fasting high-density lipoprotein (HDL) cholesterol following ketogenic diet or exogenous ketone supplementation. Serum HDL will be analyzed by clinical chemistry methods. Mean change from baseline to 12 weeks will be reported. |
Baseline to 12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Publications générales
- Pereira HM, Larson RD, Bemben DA. Menstrual Cycle Effects on Exercise-Induced Fatigability. Front Physiol. 2020 Jun 26;11:517. doi: 10.3389/fphys.2020.00517. eCollection 2020.
- Sadoyama T, Masuda T, Miyano H. Relationships between muscle fibre conduction velocity and frequency parameters of surface EMG during sustained contraction. European Journal of Applied Physiology and Occupational Physiology. 1983;51(2):247-256. doi:10.1007/BF00455188
- De Luca CJ. The Use of Surface Electromyography in Biomechanics. Journal of Applied Biomechanics. 1997;13(2):135-163. doi:10.1123/jab.13.2.135.
- Bambaeichi E, Reilly T, Cable NT, Giacomoni M. The isolated and combined effects of menstrual cycle phase and time-of-day on muscle strength of eumenorrheic females. Chronobiol Int. 2004 Jul;21(4-5):645-60. doi: 10.1081/cbi-120039206.
- Thompson BM, Drover KB, Stellmaker RJ, Sculley DV, Janse de Jonge XAK. The Effect of the Menstrual Cycle and Oral Contraceptive Cycle on Muscle Performance and Perceptual Measures. Int J Environ Res Public Health. 2021 Oct 9;18(20):10565. doi: 10.3390/ijerph182010565.
- Tenan MS, Hackney AC, Griffin L. Maximal force and tremor changes across the menstrual cycle. Eur J Appl Physiol. 2016 Jan;116(1):153-60. doi: 10.1007/s00421-015-3258-x. Epub 2015 Sep 13.
- Bouchard TP, Fehring RJ, Mu Q. Quantitative versus qualitative estrogen and luteinizing hormone testing for personal fertility monitoring. Expert Rev Mol Diagn. 2021 Dec;21(12):1349-1360. doi: 10.1080/14737159.2021.2000393. Epub 2021 Dec 3.
- Papaioannou S, Aslam M, Al Wattar BH, Milnes RC, Knowles TG. User's acceptability of OvuSense: a novel vaginal temperature sensor for prediction of the fertile period. J Obstet Gynaecol. 2013 Oct;33(7):705-9. doi: 10.3109/01443615.2013.817984.
- Thiyagarajan DK, Basit H, Jeanmonod R. Physiology, Menstrual Cycle. 2024 Sep 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500020/
- Li D, Zhang L, Wang X. The Effect of Menstrual Cycle Phases on Approach-Avoidance Behaviors in Women: Evidence from Conscious and Unconscious Processes. Brain Sci. 2022 Oct 21;12(10):1417. doi: 10.3390/brainsci12101417.
- Corbie-Smith GM, Durant RW, St George DM. Investigators' assessment of NIH mandated inclusion of women and minorities in research. Contemp Clin Trials. 2006 Dec;27(6):571-9. doi: 10.1016/j.cct.2006.05.012. Epub 2006 Jul 13.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- STUDY20250337
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Deidentified datasets (no direct identifiers; no genetic/genomic data, as none will be generated for this study)
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .